Loading market data...

Goldline Pharmaceutical IPO

Pharmaceuticals - Listed on 19 May 2026

+39.0% listing gain
Issue Price (Upper)
Rs 43
Listing Price
Rs 59.75
Closing Price (NSE)
Rs 56.77
Total Subscription
840.81x

Goldline Pharmaceutical IPO listing summary

Goldline Pharmaceutical (Pharmaceuticals) closed its IPO window in 2026 and listed on NSE and BSE on 19 May 2026 at an upper band issue price of Rs 43, opening at Rs 59.75 for a listing gain of +39.0% and closing day one at Rs 56.77 (+32.0% on closing basis). The IPO was subscribed 840.81x overall - QIB 180.22x, HNI/NII 1662.39x, Retail 881.15x. The total issue size was Rs 11.61 Cr (Fresh Issue Rs 11.61 Cr, OFS Rs 0 Cr). IPO GMP data, subscription trends across Day 1 - Day 3 and Nifty performance around the listing window are detailed below.

Listing day performance

Listing Gain (Open)
+38.95%
Listing Gain (Close)
+32.02%
Day Change After Listing
-4.99%
Retail Quota
35.0%

Subscription breakdown

Final (Day 3) subscription

Number of times each investor category subscribed by close of Day 3.

QIB180.22x
HNI / NII1662.39x
Retail881.15x
Overall840.81x

Day-wise overall subscription

How overall subscription built up across the three-day issue window.

Day 122.35x
Day 2100.21x
Day 3 (Final)840.81x

Goldline Pharmaceutical IPO GMP history

Grey market premium (GMP) tracked day-by-day across the IPO window. Absolute GMP is the premium in rupees over the upper issue price; GMP % is that premium as a percent of the issue price.

DayGMP (Rs)GMP %
Day 1Rs 5+11.63%
Day 2Rs 15+34.88%
Day 3Rs 17+39.53%
Day 4Rs 17+39.53%
Day 5Rs 25+58.14%

GMP Prediction vs IPOGyani AI Prediction

Comparison between market-based GMP prediction and IPOGyani's AI-powered listing gain prediction.

GMP Prediction Range
11.6%-58.1%
IPOGyani AI Prediction
-
Actual Listing Gain
+39.0%

Issue & financials

Issue SizeRs 11.61 Cr
Fresh IssueRs 11.61 Cr
OFSRs 0 Cr
IPO PE10.49
Peer / Sector PE-
PE vs Sector Ratio-
Latest EBITDA (Cr)20.78
Debt / Equity1.50

Market context at listing

How the broader market moved around the Goldline Pharmaceutical IPO window. Helpful for isolating how much of the listing gain came from company fundamentals vs. market tailwind.

Nifty 3D Return+0.32%
Nifty 1W Return+0.32%
Nifty 1M Return-1.88%
Nifty during IPO window+1.48%

Goldline Pharmaceutical IPO - FAQs

What was the listing gain of Goldline Pharmaceutical IPO?

Goldline Pharmaceutical IPO listed at +39.0% versus the upper issue price of Rs 43 on 19 May 2026.

How many times was Goldline Pharmaceutical IPO subscribed?

Goldline Pharmaceutical IPO was subscribed 840.81x overall. QIB portion was subscribed 180.22x, HNI / NII 1662.39x and Retail 881.15x.

What was the IPO GMP for Goldline Pharmaceutical?

IPO GMP started at Rs 5 on Day 1 and moved to Rs 25 by the close of the issue window. See the day-by-day GMP table above for the full trajectory.

Other IPOs listed in 2026

Browse listed IPOs by year